ERBB2 and metastatic neoplasm: Items in Tables 1–3 and relative elucidation can be of use in guiding treatment in case of therapeutic decisions in HR+/HER2- MBC patients with multiple comorbidities, early recurring disease, and ab initio metastatic disease.